Amgen Presents New Data On Talimogene Laherparepvec As Single Agent And Combination Therapy In Metastatic Melanoma At ASCO
June 02, 2014 at 07:46 AM EDT
Amgen (NASDAQ: AMGN) today announced new data from two key clinical trials that support the potential of talimogene laherparepvec, a ...